Abstract
In the case of vascular injury, a complex process (of clotting) starts, involving mainly platelets and coagulation factors. This process in healthy humans is known as hemostasis, but when it is deregulated (thrombosis), it can be the cause of important cardiovascular diseases. Nowadays, the aging of the population and unhealthy lifestyles increase the impact of thrombosis, and therefore there is a need for tools to provide a better understanding of the hemostasis mechanisms, as well as more cost-effective diagnosis and control devices. This study proposes a novel microflow chamber, with interchangeable biomimetic surfaces to evaluate global hemostasis, using reduced amounts of blood sample and reagents, and also a minimized time required to do the test. To validate the performance of this novel device, a study on the new oral anticoagulant Apixaban (APIX) has been performed and compared to previous conventional techniques. The test shows an excellent agreement, while the amount of the required sample has been reduced (only 100 µL is used), and the amount of reagent as well. An imprinted electrode embedded in the chamber in order to measure the impedance during the coagulation process. This approach distinguishes the impedance behavior of plasma poor in platelets (PPP) and plasma rich in platelets (PRP) for the first time.
Highlights
Hemostasis is the result of the collaboration between plasma and blood cells to stop bleeding during the initial steps of wound healing
In the case of vascular injury, a complex process starts, involving mainly platelets and coagulation factors. This process in healthy humans is known as hemostasis, but when it is deregulated, it can be the cause of important cardiovascular diseases
The aging of the population and unhealthy lifestyles increase the impact of thrombosis, and there is a need for tools to provide a better understanding of the hemostasis mechanisms, as well as more cost-effective diagnosis and control devices
Summary
There is a need to measure the effectiveness of these treatments, especially near the patient.2T.1h.eMusiceroofflobwioCmhiammebteicr mDeicsrigonfluaniddicMcahnaunfnacetlusrfionrgstudying the hemostasis process reduces the time and the number of samples required, and provides a tool to provide results near the patient.The microfluidic device has three main parts: A polydimethylsiloxane (PDMS) part that contains a2n. There is a need to measure the effectiveness of these treatments, especially near the patient. 2T.1h.eMusiceroofflobwioCmhiammebteicr mDeicsrigonfluaniddicMcahnaunfnacetlusrfionrgstudying the hemostasis process reduces the time and the number of samples required, and provides a tool to provide results near the patient. The microfluidic device has three main parts: A polydimethylsiloxane (PDMS) part that contains a2n. MopaetnermiailcsraonflduiMdiectchhoadnsnel, and it has been manufactured by conventional lithography methods, with a glass-cover to mimic the vasculature tissue and a 3D-printed frame, see Figure 1b. The goal of t2h.e1.pMrinictreodflofwramCheaimsbteoraDpepsligynparnedssMuraenounfacthtuerignlgass in order to seal the channel. Two springs that are embeTdhdeedmiincrtohfleufirdaicmdee(vFiicgeuhraes1tch)raeellomwaitnhepaerxtcs:haAnpgoeloyfditmheetghlyaslssiltooxmanoerp(PhDoMlogSi)cpaallryt tchhaatrcaoctnetraiiznes tahne othpreonmmbiicarfoteflrutihdeictecshtasn. Nel, and it has been manufactured by conventional lithography methods, withAasgslhasosw-cnovinerFtiogumreim1icthtehemvicarsocfulluaitduircePtDissMuSe apnadrtah3aDs a-pcrhinatnendeflr(awmide,thse(ewF=ig5u0r0e μ1bm. )T, hleenggothal(oLf =th1e0pmrimnt)e, ddefrpatmh e(dis=to50apμpmly)).pTrewssousriedoenchthaenngelalsssarine omraddeer twoistehaal t1h.5e cmhmanpnueln. CThwerotsopcroinngnsetchtawt iatrhe tehme binedledteadnidn othuetlfertaomfeth(Feigduerveic1ec.)Failnloawllyt,hteheexcchhaanngneeloifsthseeagleladsswtiothmtohrephgolalsosg,icwahlliychchiasrpacrteevriiozue stlhye ctoharotemdbwi iatfhtecrotlhlaegteenstasn. D placenta tissue factor to mimic blood vessel structure Two springs that are embeTdhdeedmiincrtohfleufirdaicmdee(vFiicgeuhraes1tch)raeellomwaitnhepaerxtcs:haAnpgoeloyfditmheetghlyaslssiltooxmanoerp(PhDoMlogSi)cpaallryt tchhaatrcaoctnetraiiznes tahne othpreonmmbiicarfoteflrutihdeictecshtasn. nel, and it has been manufactured by conventional lithography methods, withAasgslhasosw-cnovinerFtiogumreim1icthtehemvicarsocfulluaitduircePtDissMuSe apnadrtah3aDs a-pcrhinatnendeflr(awmide,thse(ewF=ig5u0r0e μ1bm. )T, hleenggothal(oLf =th1e0pmrimnt)e, ddefrpatmh e(dis=to50apμpmly)).pTrewssousriedoenchthaenngelalsssarine omraddeer twoistehaal t1h.5e cmhmanpnueln. cThwerotsopcroinngnsetchtawt iatrhe tehme binedledteadnidn othuetlfertaomfeth(Feigduerveic1ec.)Failnloawllyt,hteheexcchhaanngneeloifsthseeagleladsswtiothmtohrephgolalsosg,icwahlliychchiasrpacrteevriiozue stlhye ctoharotemdbwi iatfhtecrotlhlaegteenstasn. d placenta tissue factor to mimic blood vessel structure.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
